Wells Fargo’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-1,231
| Closed | – | – | 7899 |
|
|
2022
Q3 | $0 | Buy |
1,231
+5
| +0.4% | +$2 | ﹤0.01% | 7833 |
|
|
2022
Q2 | $0 | Buy |
1,226
+10
| +0.8% | +$5 | ﹤0.01% | 7928 |
|
|
2022
Q1 | $1K | Buy |
1,216
+3
| +0.2% | +$3 | ﹤0.01% | 6927 |
|
|
2021
Q4 | $3K | Hold |
1,213
| – | – | ﹤0.01% | 6852 |
|
|
2021
Q3 | $6K | Buy |
1,213
+612
| +102% | +$2.69K | ﹤0.01% | 6351 |
|
|
2021
Q2 | $2K | Sell |
601
-100,783
| -99% | -$513K | ﹤0.01% | 6592 |
|
|
2021
Q1 | $739K | Buy |
101,384
+83,300
| +461% | +$685K | ﹤0.01% | 4455 |
|
|
2020
Q4 | $138K | Buy |
18,084
+5,696
| +46% | +$38.1K | ﹤0.01% | 5234 |
|
|
2020
Q3 | $112K | Sell |
12,388
-3,155
| -20% | -$23.9K | ﹤0.01% | 5217 |
|
|
2020
Q2 | $131K | Buy |
15,543
+5,934
| +62% | +$39K | ﹤0.01% | 5097 |
|
|
2020
Q1 | $47K | Sell |
9,609
-374
| -4% | -$2.91K | ﹤0.01% | 5362 |
|
|
2019
Q4 | $72K | Buy |
9,983
+11
| +0.1% | +$99 | ﹤0.01% | 5409 |
|
|
2019
Q3 | $107K | Buy |
9,972
+253
| +3% | +$2.71K | ﹤0.01% | 5293 |
|
|
2019
Q2 | $126K | Buy |
9,719
+230
| +2% | +$3.05K | ﹤0.01% | 5204 |
|
|
2019
Q1 | $94K | Buy |
9,489
+89
| +0.9% | +$829 | ﹤0.01% | 5152 |
|
|
2018
Q4 | $97K | Buy |
+9,400
| New | +$114K | ﹤0.01% | 5297 |
|
Wells Fargo's LOGC Position: Q4 2022 in Review
Wells Fargo sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 1,231 shares.
Wells Fargo first reported a position in LOGC in Q4 2018 and held it in 16 quarters. The position peaked at $739K in Q1 2021. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.
- Wells Fargo reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
- Wells Fargo sold 1,231 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022.
- Wells Fargo first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2018 and held it in 16 quarters.
- Wells Fargo's LogicBio Therapeutics, Inc. Common Stock position peaked at $739K in Q1 2021.
- 0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.
Based on Wells Fargo's 13F filing for Q4 2022, filed 13 Feb 2023.